A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
=== Epigenetic clock analysis of human HGPS === Fibroblast samples from children with progeria syndrome exhibit accelerated epigenetic aging effects according to the epigenetic clock for skin and blood samples.
Spondyloperipheral dysplasia is an autosomal dominant disorder of bone growth. The condition is characterized by flattened bones of the spine (platyspondyly) and unusually short fingers and toes (brachydactyly). Some affected individuals also have other skeletal abnormalities, short stature, nearsightedness (myopia), hearing loss, and mental retardation. Spondyloperipheral dysplasia is a subtype of collagenopathy, types II and XI.
== Transmission == The feline panleukopenia virus is considered ubiquitous, meaning it is in virtually every place that is not regularly disinfected. The infection is highly contagious among unvaccinated cats. Antibodies against FPLV, produced by the adaptive immune system, play an important role in the feline response to the virus. Maternally-derived antibodies (MDA) efficiently protect kittens from fatal infection. This passively acquired immunity is later replaced by an active immune response obtained by vaccination or as a consequence of a natural infection. In kittens, the period of greatest susceptibility to infection is when maternal antibodies are absent, or waning, and vaccine-induced immunity has not yet fully developed. Free-roaming cats are thought to be exposed to the virus during their first year of life. Those that develop a subclinical infection or survive acute illness mount a robust, long-lasting, protective immune response. An infected cat sheds large amounts of virus in all body secretions including feces, vomit, urine, saliva, and mucus during the acute phase of illness. It can continue to shed the virus for as long as six weeks after recovery. Subclinically ill cats can also shed the virus in body secretions. The virus can be carried or transferred on an infected object (such as bedding, food dishes, fur) or by other animals, fleas, and humans (see: fomites). It persists long after evidence of the original body secretion has faded away, and can be transported long distances.
=== Dysfunction of ejaculatory reflex === Ejaculatory dysfunction is when a male is unable to ejaculate properly at the time of sexual climax. Ejaculatory reflex dysfunction is one of the leading causes in male infertility. Some conditions in which ejaculatory reflex dysfunction is observed is multiple sclerosis, diabetic neuropathy, spinal cord injuries, or side effects of certain medications. Examples of dysfunction of ejaculatory reflex include:
Metastatic prostate cancer (mPC) in men in combination with a gonadotropin-releasing hormone (GnRH) analogue or surgical castration at 50 mg/day Locally advanced prostate cancer (LAPC) in men as a monotherapy at 150 mg/day (not approved for this use in the United States) In Japan, bicalutamide is uniquely used at a dosage of 80 mg/day both in combination with castration and as a monotherapy in the treatment of prostate cancer. Bicalutamide is also employed for the following off-label (non-approved) indications:
Sources: en.wikipedia.org
While the 2015 DGA report does advise for a reduced level of consumption of red and processed meats, the 2015–2020 DGA key recommendations recommend that a variety of protein foods be consumed, including both vegetarian and non-vegetarian sources of protein.
would often encounter the Iraqi 3rd Armored Division in their theater of operations. Once the 1st Marine Division reached Kuwait International Airport they found what remained of the Iraqi 12th Armored Brigade, 3rd Armored Division defending it. The Marines destroyed 30 to 40 Iraqi T-72 tanks which had taken up defensive positions around the airport. The Iraqi 3rd Armored Division losses included more than 250 T-55/62s and 70 T-72 tanks by the end of combat operations. The Iraqi 3rd Armored Division would be totally destroyed. The 2nd Marine Division played a major role repelling the attempted Iraqi invasion of Saudi Arabia which is known as the Battle of Khafji. The 2nd Marine Division also faced heavy resistance during the Battle of Kuwait International Airport. The battle featured the "Reveille Engagement" which went on to become the largest tank battle in United States Marine Corps' entire history. Marine Reserve unit Bravo Company, 4th Tank Battalion, 4th Marine division was assigned to the 2nd Marine Division. Bravo Company destroyed a total of 119 enemy vehicles and took over 800 POWs by the end of combat operations. The 1st Tank Battalion claimed 50 Iraqi T-55 and T-62 tanks and 25 APCs. The 3rd Battalion claimed 57 T-55s and T-62s along with 5 T-72s, 7 APCs, and 10 trucks. The 8th Battalion destroyed more than three dozen tanks and a number of other vehicles. U.S. Marine Corps armor units would destroy hundreds of Iraqi tanks by the end of combat operations. U.S.
== Fragments == Big dynorphin1-32 is the primary endogenously documented big dynorphin form, but various shorter big dynorphin fragments have been synthesized for research purposes. These include (2-32), (2-26), (9-19) forms.
When in 1863 the Association of Serbian Philology commemorated the death of Cyril a thousand years earlier, its president Dimitrije Matić talked of the creation of an "ethnically pure" Slavonic people, "With God’s help, there should be a whole Slavonic people with purely Slavonic faces and of purely Slavonic character." After World War I the creation of the Kingdom of Yugoslavia, under Serbian royalty of the Karađorđević dynasty, united most Southern Slavic-speaking nations regardless of religion and cultural background. The only ones they did not unite with were the Bulgarians. Still, in the years after the Second World War, there were proposals to incorporate Bulgaria into a Greater Yugoslavia thus uniting all south Slavic-speaking nations into one state. The idea was abandoned after the split between Josip Broz Tito and Joseph Stalin in 1948. This led to some bitter sentiment between the people of Yugoslavia and Bulgaria in the aftermath. At the end of the Second World War, the Partisans' mixed heritage leader Josip Broz Tito became Yugoslav president, and the country become a socialist republic, with the motto of "Brotherhood and Unity" between its various Slavic peoples.
An example of a depsipeptide drug is the anticancer agent romidepsin, a known histone deacetylase inhibitor (HDACi). It was first isolated as a fermentation product from the soil bacterium Chromobacterium violaceum by the Fujisawa Pharmaceutical Company. Streptogramins, specifically streptogramin B, are depsipeptides that bind to the 50S subunit of bacterial ribosomes. Etamycin was shown in preliminary data in 2010 to have potent activity against MRSA in a mouse model. Several depsipeptides from Streptomyces exhibit antimicrobial activity. These form a new, potential class of antibiotics known as acyldepsipeptides (ADEPs). ADEPs target and activate casein lytic protease (ClpP) to initiate uncontrolled peptide and unfolded protein degradation, killing many Gram-positive bacteria. Depsipeptides can be formed through a Passerini reaction.
Sources: en.wikipedia.org
=== Antiquity === The presence and diseases of the thyroid have been noted and treated for thousands of years. In 1600 BCE burnt sponge and seaweed (which contain iodine) were used within China for the treatment of goitres, a practice which has developed in many parts of the world. In Ayurvedic medicine, the book Sushruta Samhita written about 1400 BCE described hyperthyroidism, hypothyroidism and goitre. Aristotle and Xenophon in the fifth century BCE describe cases of diffuse toxic goitre. Hippocrates and Plato in the fourth century BCE provided some of the first descriptions of the gland itself, proposing its function as a salivary gland. Pliny the Elder in the first century BCE referred to epidemics of goitre in the Alps and proposed treatment with burnt seaweed, a practice also referred to by Galen in the second century, referred to burnt sponge for the treatment of goitre. The Chinese pharmacology text Shennong Ben Cao Jing, written ca. 200–250, also refers to goitre.
The World Organization of the Scout Movement (WOSM ), branded as World Scouting since 2024, is the largest and, after the Order of World Scouts (formed in 1911), is the second-oldest international organisation in the Scout Movement, having been established in 1922 as The International Conference of the Boy Scout Movement. It has 176 members. These members are national scout organisations that founded WOSM or have subsequently been recognised by WOSM, which in 2025 collectively have around 51.4 million participants (up from 43 million in 2022), and a reach of 60 million young people. Its operational headquarters is in Kuala Lumpur, Malaysia, although it is legally based in Geneva, Switzerland. WOSM's stated mission is "to contribute to the education of young people, through a value system based on the Scout Promise and Scout Law, to help build a better world where people are self-fulfilled as individuals and play a constructive role in society". WOSM operates through conferences of its member organisation representatives, its committee and its full-time bureau, structured into regions. It is associated with three World Scout Centres. A World Scout Jamboree is held approximately every four years under its auspices and it organizes World Scout Moots for 17- to 26-year-olds and previously organised World Scout Indabas, a gathering for Scout leaders. The World Scout Foundation is a separately governed fund, supported by donations, for the development of WOSM associated programmes. WOSM is the counterpart of the World Association of Girl Guides and Girl Scouts (WAGGGS).
In 1912, Frederick Gowland Hopkins demonstrated that unknown accessory factors found in milk, other than carbohydrates, proteins, and fats were necessary for growth in rats. Hopkins received a Nobel Prize for this discovery in 1929. By 1913, one of these substances was independently discovered by Elmer McCollum and Marguerite Davis at the University of Wisconsin–Madison, and Lafayette Mendel and Thomas Burr Osborne at Yale University. McCollum and Davis ultimately received credit because they submitted their paper three weeks before Mendel and Osborne. Both papers appeared in the same issue of the Journal of Biological Chemistry in 1913. The "accessory factors" were termed "fat soluble" in 1918, and later "vitamin A" in 1920. In 1919, Harry Steenbock (University of Wisconsin–Madison) proposed a relationship between yellow plant pigments (β-carotene) and vitamin A. In 1931, Swiss chemist Paul Karrer described the chemical structure of vitamin A. Retinoic acid and retinol were first synthesized in 1946 and 1947 by two Dutch chemists, David Adriaan van Dorp and Jozef Ferdinand Arens.
Seeing an opportunity in Napoleon I's historic defeat, Prussia, Sweden and several other German states switched sides, joining Russia, the United Kingdom and others opposing Napoleon. Napoleon vowed that he would create a new army as large as the one he had sent into Russia, and quickly built up his forces in the east from 30,000 to 130,000 and eventually to 400,000. Napoleon inflicted 40,000 casualties on the Allies at Lützen (2 May 1813) and Bautzen (20–21 May 1813). Both battles involved forces of over 250,000, making them some of the largest conflicts of the wars so far. Klemens von Metternich in November 1813 offered Napoleon the Frankfurt proposals. They would allow Napoleon to remain Emperor but France would be reduced to its "natural frontiers" and lose control of most of Italy and Germany and the Netherlands. Napoleon still expected to win the wars, and rejected the terms. By 1814, as the Allies were closing in on Paris, Napoleon I did agree to the Frankfurt proposals, but it was too late and he rejected the new harsher terms proposed by the Allies.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.